Yan Sijia, Zhou Mi, Zhu Xiaojian, Xiao Yi
Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
J Cereb Blood Flow Metab. 2025 May 2:271678X251332492. doi: 10.1177/0271678X251332492.
Chimeric antigen receptor T (CAR-T) cells have made brilliant achievements in the treatment of many kinds of malignant tumors, and six kinds of CAR-T products have been approved by the Food and Drug Administration (FDA), bringing new hope for the treatment of diseases. However, the complications associated with CAR-T cell therapy should not be ignored. Neurological complications often jeopardize patients' lives, including immune effector cell-associated neurotoxicity syndrome, cerebrovascular accidents, movement and neurocognitive treatment-emergent adverse events. The current knowledge of the mechanism and treatment of these complications is still insufficient, which is a direction that needs to be solved in the future.
嵌合抗原受体T(CAR-T)细胞在多种恶性肿瘤的治疗中取得了辉煌成就,六种CAR-T产品已获美国食品药品监督管理局(FDA)批准,为疾病治疗带来了新希望。然而,与CAR-T细胞疗法相关的并发症不容忽视。神经并发症常常危及患者生命,包括免疫效应细胞相关神经毒性综合征、脑血管意外、运动及神经认知治疗中出现的不良事件。目前对于这些并发症的机制和治疗的了解仍不充分,这是未来需要解决的一个方向。